These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27279380)

  • 21. Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Maiorino MI; Chiodini P; Bellastella G; Capuano A; Esposito K; Giugliano D
    Diabetes Care; 2017 Apr; 40(4):614-624. PubMed ID: 28325801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical inertia in basal insulin-treated patients with type 2 diabetes - Results from a retrospective database study in Japan (JDDM 43).
    Satoh J; Andersen M; Bekker Hansen B; Larsen Thorsted B; Tutkunkardas D; Zacho M; Maegawa H
    PLoS One; 2018; 13(9):e0198160. PubMed ID: 30226870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.
    Trautmann ME; Vora J
    Diabet Med; 2018 Jun; 35(6):694-706. PubMed ID: 29478255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Basal insulin intensification in type 2 diabetes: a key role for GLP-1 receptor agonists.
    Charbonnel PB
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S1-6S2. PubMed ID: 26774014
    [No Abstract]   [Full Text] [Related]  

  • 25. When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump.
    Cohen O; Filetti S; Castañeda J; Maranghi M; Glandt M
    Diabetes Care; 2016 Aug; 39 Suppl 2():S180-6. PubMed ID: 27440831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort study.
    Thomsen RW; Baggesen LM; Svensson E; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetes Obes Metab; 2015 Aug; 17(8):771-80. PubMed ID: 25929277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
    Rosenstock J; Fonseca VA; Gross JL; Ratner RE; Ahrén B; Chow FC; Yang F; Miller D; Johnson SL; Stewart MW; Leiter LA;
    Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing Glucagon-like peptide-1 receptor agonists versus metformin in drug-naive patients: A nationwide cohort study.
    Sørensen KK; Gerds TA; Køber L; Loldrup Fosbøl E; Poulsen HE; Møller AL; Andersen MP; Pedersen-Bjergaard U; Torp-Pedersen C; Zareini B
    J Diabetes; 2024 Oct; 16(10):e70000. PubMed ID: 39364788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.
    Jia W; Xiao X; Ji Q; Ahn KJ; Chuang LM; Bao Y; Pang C; Chen L; Gao F; Tu Y; Li P; Yang J
    Lancet Diabetes Endocrinol; 2015 Apr; 3(4):254-62. PubMed ID: 25754414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.
    Rathmann W; Bongaerts B; Kostev K
    Diabetes Obes Metab; 2016 Aug; 18(8):840-3. PubMed ID: 27062643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycaemic control in patients with type 2 diabetes switching from premixed insulin to long-acting basal insulin analogue plus oral antidiabetic drugs: an observational study.
    Gómez-Peralta F; Carramiñana-Barrera F; Félix-Redondo FJ; Fraile-Gómez J;
    Int J Clin Pract; 2012 Oct; 66(10):959-68. PubMed ID: 22994330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes.
    Hughes E
    Prim Care Diabetes; 2016 Jun; 10(3):202-9. PubMed ID: 26776758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
    Darmon P; Raccah D
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents.
    Kim K; Unni S; McAdam-Marx C; Thomas SM; Sterling KL; Olsen CJ; Johnstone B; Mitchell M; Brixner D
    J Manag Care Spec Pharm; 2019 Mar; 25(3):314-322. PubMed ID: 30816811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options.
    Raccah D
    Diabetes Metab; 2017 Apr; 43(2):110-124. PubMed ID: 28169086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prandial insulin versus glucagon-like peptide-1 added to basal insulin: comparative effectiveness in the community practice setting.
    Digenio A; Karve S; Candrilli SD; Dalal M
    Postgrad Med; 2014 Oct; 126(6):49-59. PubMed ID: 25414934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
    Lugner M; Sattar N; Miftaraj M; Ekelund J; Franzén S; Svensson AM; Eliasson B
    Cardiovasc Diabetol; 2021 Mar; 20(1):67. PubMed ID: 33752680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
    Rosenstock J; Blonde L; Aroda VR; Frias J; Souhami E; Ji C; Niemoeller E; Del Prato S
    Diabetes Obes Metab; 2021 Jun; 23(6):1331-1341. PubMed ID: 33565209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.